A new Northbrook pharma will work to bring its obesity treatment to market that it says holds advantages over Ozempic and its ...

Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) prior to bariatric surgery was safe but wasn’t associated with ...

For the first time in decades, the prevalence of obesity has not increased in the USA, according to the latest National Health and Nutrition Examination Survey from the US Centers for Disease Control ...

Structure Therapeutics has the potential to have a best-in-class GLP-1 agonist drug for treatment of patients with obesity. Learn more on GPCR stock here.

Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...

For 52-year-old American property agent and aesthetician Kathryn Dean, diabetes drugs semaglutide and tirzepatide were key to achieving long-term weight loss – and preventing type-2 diabetes.

Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.

When you're taking GLP-1 medications for weight loss, it's easy for nutrition to get overlooked because while semaglutide ...

The use of glucagon-like peptide 1 (GLP-1) agonists in patients with inflammatory bowel disease (IBD) was associated with few episodes of disease exacerbation and resulted in a significant decrease in ...

This intrusive, but common phenomenon can take over your life, affecting your state of mind and eating habits. Weight-loss drugs show promise in quieting these thoughts.